Gain Therapeutics, Inc. 8-K

What Happened

• Gain Therapeutics, Inc. filed an 8-K on June 29, 2026, announcing that the U.S. Food and Drug Administration has authorized the company’s Investigational New Drug (IND) application for GT-02287.
• The FDA decision clears the way to start the Company’s Phase 2 clinical development of oral GT-02287 in Parkinson’s disease (with or without a GBA1 mutation), with study initiation anticipated in the third quarter of 2026.

Key Details

• Date of announcement: June 29, 2026 (Form 8-K filed).
• Regulatory action: FDA authorized IND for GT-02287, enabling U.S. enrollment.
• Planned study: Phase 2a oral study in treated and untreated participants with early Parkinson’s disease; sites in the U.S., Australia, and selected European centers.
• Timeline and prior data: Both Phase 1a and Phase 1b were conducted in Australia; Phase 2 initiation is expected in Q3 2026.

Why It Matters

• IND authorization is a material regulatory milestone that permits Gain to expand GT-02287’s clinical program into the U.S., potentially accelerating patient enrollment and development progress.
• For investors, this creates a clear near-term program catalyst (Phase 2 start expected Q3 2026) but does not guarantee clinical success or regulatory approval; the filing includes standard forward‑looking statement cautions and points to the company’s Form 10-K for risk factors.